Back to News
Market Impact: 0.25
Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile
Source: GlobeNewswire
Healthcare & BiotechTechnology & Innovation
Avalyn reported results supporting its strategy of delivering established antifibrotic medicines directly to the lungs. The approach is intended to maximize local drug exposure while reducing systemic exposure and improving tolerability, providing a positive validation of its inhaled-treatment platform.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
AVLN0.72
More News
- Taiwan benchmark Taiex rises to record intraday high as tech stocks advance
- AMD joins the $1 trillion club as chip rally surges - our AI Strategy saw it early
- Here's who we know is going to the Trump-Xi dinner so far
- +17% in a single session: This AI-picked stock catches a data-center breakout
- Asia stocks rise tracking U.S. tech rally; Trump-Xi meeting eyed
- Perpetual underdog AMD nips at Nvidia's heels as it joins the $1T club